45 related articles for article (PubMed ID: 19424593)
1. p15 promoter methylation - a novel prognostic marker in glioblastoma patients.
Wemmert S; Bettscheider M; Alt S; Ketter R; Kammers K; Feiden W; Steudel WI; Rahnenführer J; Urbschat S
Int J Oncol; 2009 Jun; 34(6):1743-8. PubMed ID: 19424593
[TBL] [Abstract][Full Text] [Related]
2. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification.
Camacho CV; Todorova PK; Hardebeck MC; Tomimatsu N; Gil del Alcazar CR; Ilcheva M; Mukherjee B; McEllin B; Vemireddy V; Hatanpaa K; Story MD; Habib AA; Murty VV; Bachoo R; Burma S
Oncogene; 2015 Feb; 34(8):1064-72. PubMed ID: 24632607
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
Etcheverry A; Aubry M; de Tayrac M; Vauleon E; Boniface R; Guenot F; Saikali S; Hamlat A; Riffaud L; Menei P; Quillien V; Mosser J
BMC Genomics; 2010 Dec; 11():701. PubMed ID: 21156036
[TBL] [Abstract][Full Text] [Related]
4. Predominance of MGMT promoter methylation among Pakistani glioblastoma patients.
Muhammad N; Fasih S; Malik B; Hameed S; Loya A; Rashid MU
Mol Biol Rep; 2024 Mar; 51(1):433. PubMed ID: 38520591
[TBL] [Abstract][Full Text] [Related]
5. The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?
Christoph S; Alicia S; Fritz T; Vanessa T; Ralf K; Jin KY; Stefan L; Joachim O
Acta Neurochir (Wien); 2023 Jun; 165(6):1635-1644. PubMed ID: 37083881
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of
Sippl C; Urbschat S; Kim YJ; Senger S; Oertel J; Ketter R
Oncol Lett; 2018 Feb; 15(2):1600-1606. PubMed ID: 29434855
[TBL] [Abstract][Full Text] [Related]
7. Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.
Meng W; Jiang Y; Ma J
Cancer Manag Res; 2017; 9():411-425. PubMed ID: 29033608
[TBL] [Abstract][Full Text] [Related]
8. Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy.
Urbschat S; Sippl C; Engelhardt J; Kammers K; Oertel J; Ketter R
Mol Cytogenet; 2017; 10():16. PubMed ID: 28484518
[TBL] [Abstract][Full Text] [Related]
9. Current Perspectives on Epigenetic Modifications by Dietary Chemopreventive and Herbal Phytochemicals.
Guo Y; Su ZY; Kong AN
Curr Pharmacol Rep; 2015 Aug; 1(4):245-257. PubMed ID: 26328267
[TBL] [Abstract][Full Text] [Related]
10. Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors.
Ferreira WA; Araújo MD; Anselmo NP; de Oliveira EH; Brito JR; Burbano RR; Harada ML; Borges Bdo N
PLoS One; 2015; 10(8):e0137259. PubMed ID: 26317630
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis.
Chen C; Wang F; Cheng Y; Cheng Y; Ren X; Huai H
Int J Clin Exp Med; 2015; 8(4):6553-62. PubMed ID: 26131285
[TBL] [Abstract][Full Text] [Related]
12. The methylation of a panel of genes differentiates low-grade from high-grade gliomas.
Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Kleszcz R; Sherba A; Baer-Dubowska W
Tumour Biol; 2015 May; 36(5):3831-41. PubMed ID: 25563195
[TBL] [Abstract][Full Text] [Related]
13. The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.
Yang H; Wei D; Yang K; Tang W; Luo Y; Zhang J
Neurochem Res; 2014 Dec; 39(12):2277-87. PubMed ID: 25230908
[TBL] [Abstract][Full Text] [Related]
14. Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.
Wang X; Zhu YB; Cui HP; Yu TT
Tumour Biol; 2014 Sep; 35(9):9035-43. PubMed ID: 24908414
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease.
Krajnović M; Jovanović MP; Mihaljević B; Anđelić B; Tarabar O; Knežević-Ušaj S; Krtolica K
Clin Transl Sci; 2014 Oct; 7(5):384-90. PubMed ID: 24815848
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.
Zhang K; Wang XQ; Zhou B; Zhang L
Fam Cancer; 2013 Sep; 12(3):449-58. PubMed ID: 23397067
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.
Krajnović M; Radojković M; Davidović R; Dimitrijević B; Krtolica K
Med Oncol; 2013 Mar; 30(1):441. PubMed ID: 23275143
[TBL] [Abstract][Full Text] [Related]
18. The future role of personalized medicine in the treatment of glioblastoma multiforme.
Li J; Di C; Mattox AK; Wu L; Adamson DC
Pharmgenomics Pers Med; 2010; 3():111-27. PubMed ID: 23226047
[TBL] [Abstract][Full Text] [Related]
19. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE
J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413
[TBL] [Abstract][Full Text] [Related]
20. Environmental chemical exposures and human epigenetics.
Hou L; Zhang X; Wang D; Baccarelli A
Int J Epidemiol; 2012 Feb; 41(1):79-105. PubMed ID: 22253299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
